Jeffrey Demain is a Rheumatology/Immunology physician affiliated with University of Alaska Anchorage. OpenAlex indexes 55 publications with 2,775 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
510 W Tudor Rd Ste 1
Anchorage, AK 995036649
Telephone
907-744-1944Provider last certified this registry record 8 Apr 2025.
Industry payments
29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI US SERVICES INC.Program year202518 payments$39,414openpaymentsdata.cms.gov ↗
- Blueprint Medicines CorporationProgram year202521 payments$28,181openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
35.2%Iron, parenteral preparations35.2%Ferric carboxymaltose86%Ferric derisomaltose14%Part B, office-administered≥45 patientsRespiratory
32%Thymic Stromal Lymphopoietin Blocker32%Tezepelumab-ekko100%Part B, office-administered≥15 patientsCardiovascular
17.2%Other lipid modifying agents17.2%Inclisiran100%Part B, office-administered≥45 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Values-Based Healthcare and the Quintuple Aim: Connection, Compassion, Equity, & Stewardship
The Journal of Allergy and Clinical Immunology In Practice
2026 - 10 ways to better understand climate change and allergic diseases in clinical settings
Annals of Allergy Asthma & Immunology
2025 - Insect Allergy: Barriers in Training and Practice—A Work Group Report of the AAAAI Anaphylaxis Committee
The Journal of Allergy and Clinical Immunology In Practice
2025 - Growing Impact of Climate Change on Respiratory Health and Related Allergic Disorders: Need for Health Systems to Prepare
Immunology and Allergy Clinics of North America
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Joshua Mammen, MD
University of Alaska Anchorage
John Kokesh, MD
University of Alaska Anchorage
Lauren Lessard, MD
University of Alaska Anchorage
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”